• Iovance highlighted expanding commercialization of Amtagvi, citing about 2,000 commercial and clinical treatments to date.
• 2Q26 revenue ran more than 10% above guidance; year-over-year quarterly revenue growth was about 66%.
• Gross margin from cost of sales was 56% in 2Q26; cash totaled about USD 304 million as of June 30, 2026.
• Authorized treatment centers exceeded 95 across the U.S., Canada, Australia; more than 95% of addressable patients were within 200 miles of a center.
• Pipeline focus remained on lifileucel in NSCLC, with a potential commercial launch targeted for 2H27.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.